.png)
Oxford StemTech is a University of Oxford spinout company, founded by world-leading research group in stem cell-based disease models and drug discovery.
Stem Cell Reprogramming from donor's somatic cells is a difficult, complex process that is expensive to perform and labour-intensive. To tackle these bottlenecks, StemTech has developed the proprietary ReproPlex™ platform that drastically reduces the cost and hugely increases the scale of reprogramming. Importantly our method produces the highest quality - pluripotent and genomically stable stem cell lines for research. This means that StemTech can undertake big reprogramming projects for a fraction of the cost and a fraction of the time. This opens new and exciting opportunities for using stem cells in drug discovery. In addition to reprogramming, we also offer several complementary services, including bespoke drug discovery services to big pharma. iPSC quality control, lineage-specific differentiation and PBMC isolation. StemTech also has a vast iPSC repository of diseased and control iPSCs that are currently available for disease research and drug discovery.
Our mission is to create the best human cell research tools to enable a better understanding of human disease, and to allow the development of precision medicines. Our values are quality, excellence, innovation, reliability and value.